(New York, USA) DelveInsight’s Developmental and Epileptic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, developmental and epileptic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Developmental and Epileptic Encephalopathy Market Report
- As per DelveInsight analysis, the developmental and epileptic encephalopathy market size in the 7MM was approximately USD 1,371 million in 2021.
- According to the assessment done by DelveInsight, the estimated total DEE diagnosed prevalent cases in the 7MM were approximately 235K in 2021.
- Leading developmental and epileptic encephalopathy companies working in the treatment market are Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Stoke Therapeutics, BioPharm Solutions, Praxis Precision Medicines, Epygenix, Longboard Pharmaceuticals, and others.
- The promising developmental and epileptic encephalopathy therapies in the pipeline include EPX-100, EPX-200, EPX-300, XEN 496, LP 352, STK-001, JBPOS0101, Soticlestat (OV935/TAK-935), Carisbamate, NBI-921352, NBI-827104, PRAX-562, and others.
- The current therapeutic landscape of DEE in the United States is driven by current treatment practices which includes anti-epileptic drugs (AEDs), Epidiolex/Epidyolex (cannabidiol), Fintepla (Fenfluramine), Afinitor/Votubia (Everolimus), and others.
Discover which therapies are expected to grab the major developmental and epileptic encephalopathy market share @Developmental and Epileptic Encephalopathy Market Forecast
Developmental and Epileptic Encephalopathy Overview
Developmental and epileptic encephalopathy is a seizure disorder characterized by infantile spasms, a type of seizure. Spasms typically appear before the age of one. The prognosis for developmental and epileptic encephalopathy is bleak. This rare disease, typically described as progressive and incurable, is also associated with severe physical and cognitive disabilities and unexplained death.
The most common cause of epileptic encephalopathy in childhood is structural abnormalities, which can be congenital (such as cortical malformations) or acquired (such as hypoxic-ischemic after the EEG often evolves to atypical hypsarrhythmia, which is a transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.
Developmental and Epileptic Encephalopathy Epidemiology Segmentation
DelveInsight estimates that there were approximately 235K diagnosed prevalent cases of DEE in the 7MM in 2021.
Among the EU-4 countries, the diagnosed prevalent population of DEE was maximum in Germany in 2021.
The developmental and epileptic encephalopathy market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Diagnosed Prevalent Population of developmental and epileptic encephalopathy
- Treated pool of developmental and epileptic encephalopathy
Download the report to understand which factors are driving developmental and epileptic encephalopathy epidemiology trends @ https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market
Developmental and Epileptic Encephalopathy Treatment Market
Some of the general principles and approach to pediatric epilepsy treatment can be found in the epileptic encephalopathy treatment. The best anti-epileptic treatment is chosen based on the type of epilepsy syndrome. Although anti-seizure medications are commonly used, some types of seizures are notoriously difficult to control. It is the primary method of controlling epileptic seizures and is almost always the first class of therapy medications.
Some of the FDA-approved drugs used for DEE treatment include Epidiolex (Jazz Pharmaceuticals), Diacomit (Biocodex), Fintepla (Zogenix), Sabril (Lundbeck), Ztalmy (Marinus Pharmaceuticals), Afinitor Disperz/Votubia (Novartis), Sympazan (Aquestive Therapeutics), Trokendi XR (Supernus Pharmaceuticals), Onfi (Lundbeck), Banzel (Eisai Pharmaceuticals), Lamictal (GlaxoSmithKline), and others.
In some children, steroid therapy with adrenocorticotropic hormone (ACTH) or prednisone has been beneficial. When medications do not work well, a vagus nerve stimulator or the ketogenic diet may be considered in patients. Moreover, in children with seizures that begin in one area or involve only one side of the brain, epilepsy surgery may be an option. In these cases, a focal resection (removal of a single area) or a hemispherectomy (removal of the majority of one side of the brain) may be considered.
To know more about developmental and epileptic encephalopathy treatment options, visit @ https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market
Developmental and Epileptic Encephalopathy Pipeline Therapies and Key Companies
- XEN496: Xenon Pharmaceuticals
- Soticlestat: Takeda/Ovid Therapeutics
- Carisbamate: SK Life Science
- EPX-100 (Clemizole HCl): Epygenix
- NBI-921352: Neurocrine Biosciences
- STK-001: Stoke Therapeutics
- NBI-827104: Neurocrine Biosciences
- JBPOS0101: BioPharm Solutions
- PRAX-562: Praxis Precision Medicines
- EPX-200 (Lorcaserin): Epygenix
- EPX-300: Epygenix
- LP352: Longboard Pharmaceuticals
Learn more about the DEE FDA-approved drugs @ https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market
Developmental and Epileptic Encephalopathy Market Dynamics
The dynamics of developmental and epileptic encephalopathy market is anticipated to change in the coming years. Ztalmy, the first licensed therapy for CDKL5 deficiency disorder, was recently approved in the United States, boosting the developmental and epileptic encephalopathy market growth. Moreover, the void left by a lack of licensed medications will be filled by further R&D advancement. In addition, Epidiolex and Fintepla continue to add new prescribers and expand their existing prescriber base due to their strong uptake.
Furthermore, the current competitive scenario for DEE is limited to a few therapies. Currently, the DEE market appears to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to capture the potential developmental and epileptic encephalopathy market space. Emerging drugs with improved seizure control may positively impact the developmental and epileptic encephalopathy market landscape and patients’ quality of life.
However, several factors are impeding the growth of the DEE market. Rare epileptic syndromes, such as LGS, Dravet Syndrome, and CDKL5 deficiency disorder, are extremely complex and heterogeneous diseases with multiple etiologies, posing several diagnostic challenges as the disease progresses.
Scope of the Developmental and Epileptic Encephalopathy Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
- Base Year: 2021
- Developmental and Epileptic Encephalopathy Market CAGR: 15.5%
- Developmental and Epileptic Encephalopathy Market Size in 2021: USD 1,371 million
- Key Developmental and Epileptic Encephalopathy Companies: Jazz Pharmaceuticals, Biocodex, Zogenix (Acquired by UCB), Lundbeck, Marinus Pharmaceuticals, Novartis, Aquestive Therapeutics, Supernus Pharmaceuticals, Lundbeck, Eisai Pharmaceuticals, GlaxoSmithKline, Meda Pharmaceuticals, Roche, Questcor Pharmaceuticals, Mallinckrodt Pharmaceuticals, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, SK Life Science, Neurocrine Biosciences, Stoke Therapeutics, Neurocrine Biosciences, BioPharm Solutions, Praxis Precision Medicines, Epygenix, Longboard Pharmaceuticals, and others
- Key Developmental and Epileptic Encephalopathy Therapies: XEN496, Soticlestat, Carisbamate, Carisbamate, EPX-100, NBI-921352, STK-001, NBI-827104, JBPOS0101, PRAX-562, EPX-200 (Lorcaserin), EPX-300, LP352, and others
- Therapeutic Assessment: Developmental and Epileptic Encephalopathy current marketed and emerging therapies
- Developmental and Epileptic Encephalopathy Market Dynamics: Developmental and Epileptic Encephalopathy market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Developmental and Epileptic Encephalopathy Market Access and Reimbursement
Discover more about DEE drugs in development @ https://www.delveinsight.com/sample-request/developmental-and-epileptic-encephalopathies-dee-market
Table of Contents
|
1 |
Key Insights |
|
2 |
Developmental and Epileptic Encephalopathy Report Introduction |
|
3 |
Executive Summary |
|
4 |
Key Events |
|
5 |
Developmental and Epileptic Encephalopathy SWOT Analysis |
|
6 |
Developmental and Epileptic Encephalopathy Epidemiology and Market Methodology |
|
7 |
Developmental and Epileptic Encephalopathy (DEE) Market Overview at a Glance |
|
7.1 |
Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2021 |
|
7.2 |
Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2032 |
|
8 |
Developmental and Epileptic Encephalopathy Background and Overview |
|
8.1 |
West Syndrome |
|
8.2 |
Dravet Syndrome |
|
8.3 |
Lennox–Gastaut Syndrome |
|
8.4 |
Landau–Kleffner Syndrome (LKS) (Acquired Epileptic Aphasia) |
|
8.5 |
Epilepsy with Continuous Spike-and-Waves during Slow-Wave Sleep |
|
8.6 |
Doose Syndrome (myoclonic atonic epilepsy) |
|
8.7 |
CDKL5 deficiency disorder (CDD) |
|
8.8 |
Tuberous sclerosis complex (TSC) |
|
8.9 |
Genetic Epilepsy |
|
8.10 |
Biomarkers of epileptic encephalopathies |
|
9 |
Treatment of Developmental and Epileptic Encephalopathy |
|
9.1 |
Antiseizure medications |
|
9.2 |
Steroid therapy |
|
9.3 |
Other Therapies |
|
9.4 |
Epilepsy surgery |
|
9.5 |
Developmental and Epileptic Encephalopathy Treatment Algorithm |
|
10 |
Developmental and Epileptic Encephalopathy Treatment Guidelines |
|
11 |
Developmental and Epileptic Encephalopathy Epidemiology and Patient Population of 7MM |
|
11.1 |
Key Findings |
|
11.2 |
Assumptions and Rationale |
|
11.2.1 |
Dravet Syndrome |
|
11.2.2 |
Lennox-Gastaut Syndrome |
|
11.2.3 |
Ohtahara Syndrome |
|
11.2.4 |
West Syndrome |
|
11.2.5 |
Landau-Kleffner Syndrome |
|
11.2.6 |
Tuberous Sclerosis Complex |
|
11.2.7 |
CDKL5 deficiency disorder |
|
11.2.8 |
Others |
|
11.3 |
Diagnosed Prevalent Population of DEE in 7MM |
|
11.4 |
United States |
|
11.4.1 |
Diagnosed Prevalent Population of DEE in the United States |
|
11.5 |
EU-4 and UK |
|
11.5.1 |
Diagnosed Prevalence of DEE in the EU-4 and the UK |
|
11.6 |
Japan |
|
11.6.1 |
Diagnosed Prevalent Population of Developmental and Epileptic Encephalopathy in Japan |
|
12 |
Marketed Developmental and Epileptic Encephalopathy Drugs |
|
12.1 |
Key Competitor |
|
13 |
Emerging Developmental and Epileptic Encephalopathy Drugs |
|
13.1 |
Key Competitors |
|
14 |
Developmental and Epileptic Encephalopathy (DEE): 7MM Market Analysis |
|
14.1 |
Key Findings |
|
14.2 |
Developmental and Epileptic Encephalopathy Market Outlook |
|
14.3 |
Key Market Forecast Assumptions |
|
14.4 |
Attribute Analysis |
|
14.5 |
Total Market Size of Developmental and Epileptic Encephalopathy in the 7MM |
|
14.6 |
Developmental and Epileptic Encephalopathy Market Size by Current and Emerging Therapies in the 7MM |
|
14.7 |
United States Market Size |
|
14.7.1 |
Total Market Size of DEE in the United States |
|
14.7.2 |
Market Size of DEE by Current and Emerging Therapies in the United States |
|
14.8 |
EU-4 and UK Market Size |
|
14.8.1 |
Total Market size of DEE in the EU-4 and the UK |
|
14.8.2 |
Market Size of DEE by Current and Emerging Therapies in EU-4 and the UK |
|
14.9 |
Japan |
|
14.9.1 |
Total Market size of DEE in Japan |
|
14.9.2 |
Market Size of DEE by Current and Emerging Therapies in Japan |
|
15 |
Developmental and Epileptic Encephalopathy Market Drivers |
|
16 |
Developmental and Epileptic Encephalopathy Market Barriers |
|
17 |
Developmental and Epileptic Encephalopathy Unmet Needs |
|
18 |
Developmental and Epileptic Encephalopathy Market Access and Reimbursement |
|
19 |
Appendix |
|
19.1 |
Bibliography |
|
19.2 |
Report Methodology |
|
20 |
DelveInsight Capabilities |
|
21 |
Disclaimer |
|
22 |
About DelveInsight |
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services